Croma-Pharma Expands Successful Mask Range With Face Masks for Different Areas of Application
21.10.2021 12:38:00 EEST | Business Wire | Press release
Croma-Pharma (Croma) announced today the expansion of its successful mask portfolio. The carefully selected ingredients of each formulation, as well as the sheet material, are tailored to specific application areas and skin needs. The products have a pleasant texture and are suitable for all skin types.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005468/en/
@Croma (Photo: Business Wire)
The right mask for every need
The Croma mask portfolio offers two full face masks, as well as masks for specific areas of the face including the eyes, lips, and laugh lines.
Calming face mask with aloe vera, green tea and rosehip oil
The Croma calming face mask contains ingredients known for their antioxidant and soothing effects, as well as skin-regenerating properties. It replenishes the skin with vitamins and helps to protect against harmful environmental influences. Regular use may help to strengthen the skin barrier and provides optimal care for the skin. The material consists of 80 percent green tea fibers and 20 percent cupro - so not only the serum per se works to achieve the desired effect, but also the mask material itself.
Key ingredients: hyaluronic acid, rosehip oil, green tea leaf extract, aloe vera juice
Recommended retail price: EUR 59,-
Rejuvenating face mask with hyaluronic acid
This hyaluronic acid mask has long been considered to be one of Croma Pharma Skincare's most popular products. The incorporated ingredients refresh dehydrated skin, alleviate visible dryness and help to improve the skin’s elasticity. In addition to its pleasant cooling effect, the formulation may help to smooth small wrinkles and ensures a radiant complexion. Regular use can help to fight the signs of skin aging and maintain a youthful appearance.
Key ingredients: hyaluronic acid, imperata cylindrica root extract, irish moss extract
Recommended retail price: EUR 59,-
Organic cellulose masks for special facial areas
Energizing eye mask with hyaluronic acid, kiwi and cucumber extract
Croma energizing eye mask provides an instant boost of hydration. The mask is packed with soothing ingredients which sustainably improve the skin barrier function and skin elasticity. The fermented extracts nourish the skin with valuable postbiotics. The eye mask contains powerful antioxidants – including vitamin C – and helps to moisturize and reduce signs of fatigue, while providing an extra energy kick for a fresh and energized appearance.
Key ingredients: hyaluronic acid, kiwi fruit ferment, cucumber extract
Recommended retail price: EUR 55,-
Regenerating lip mask with hyaluronic acid, aloe vera and berry ferment
The regenerating lip mask infused with hyaluronic acid, aloe vera and berry ferment that deeply moisturize the delicate lip area while providing a cooling and regenerating effect. The ingredients soften and plump the lips.
Key ingredients: hyaluronic acid, aloe vera, berry ferment
Recommended retail price: EUR 55,-
Firming laugh line mask with hyaluronic acid and pomegranate extract
Croma firming mask for laugh lines is enriched with hyaluronic acid to intensely hydrate and soothe the skin of the nasolabial folds. The carefully selected ingredients include Palmitoyl hexapeptide, a biomimetic peptide that gives a firming effect and can smooth the appearance of wrinkles. Pomegranate ferment extract, a potent antioxidant, may increase skin collagen.
Key ingredients: hyaluronic acid, palmitoyl hexapeptide-12, pomegranate fermented extract
Recommended retail price: EUR 55,-
Croma expert tip - the right application
Croma Expert Tip by Dr. Monika Sulovsky, Yuvell® Committed to Beauty: “A moisturizing mask is a freshness boost for any skin type and can easily be applied in the morning or evening.
- Step 1: A face mask is always applied to a cleansed face and is used before serums or creams.
- Step 2: The mask should be left on for 15 minutes.
- Step 3: Finally, remove the mask and gently massage the excess serum into the skin.”
“Our Croma face masks have been very popular for a long time. This was also a welcome occasion for us to expand the portfolio in order to be able to offer our customers a comprehensive beauty treatment at home", explains Andreas Prinz, the Managing Director of Croma-Pharma.
Availability
The Croma masks are available via www.cromaskincareshop.com and selected partners.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses its own branded products on minimally invasive aesthetic medicine. In addition to a broad range of HA fillers produced on site, Croma also markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high-quality skincare technologies in its core strategic markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005468/en/
Contact information
CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Cromazeile 2
A-2100 Leobendorf
Tel.: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at
CROMA-PHARMA GmbH
Simone Turek
External Communications Manager
Cromazeile 2
A-2100 Leobendorf
Tel.: +43 676 846868 654
Mail: simone.turek@croma.at
Web: www.croma.at
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom